SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: January
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -3.13
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.25

02 Jul
2024

0.005

OPEN

$1.25

0.40%

HIGH

$1.26

2,607,325

LOW

$1.24

TARGET
$1.057 -15.5% downside
Franking for last dividend paid out: 50%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 0.4 1.6 xxx
DPS (cps) xxx 1.0 1.0 xxx
EPS Growth xxx 100.0% 100.0% xxx
DPS Growth xxx 1.5% - 0.2% xxx
PE Ratio xxx N/A 77.6 xxx
Dividend Yield xxx N/A 0.8% xxx
Div Pay Ratio(%) xxx 223.9% 60.1% xxx

Dividend yield today if purchased 3 years ago: 1.61%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.78

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.4
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx3,322.1 M
Book Value Per Share xxxxxxxxxxxxxxx55.4
Net Operating Cash Flow xxxxxxxxxxxxxxx42.0 M
Net Profit Margin xxxxxxxxxxxxxxx0.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx0.67 %
Return on Invested Capital xxxxxxxxxxxxxxx0.53 %
Return on Assets xxxxxxxxxxxxxxx0.35 %
Return on Equity xxxxxxxxxxxxxxx0.67 %
Return on Total Capital xxxxxxxxxxxxxxx-8.40 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx27.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx10 M
Long Term Debt xxxxxxxxxxxxxxx127 M
Total Debt xxxxxxxxxxxxxxx137 M
Goodwill - Gross xxxxxxxxxxxxxxx89 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx356 M
Price To Book Value xxxxxxxxxxxxxxx1.87

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx4.7 M
Capex % of Sales xxxxxxxxxxxxxxx0.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,132 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx262 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx14 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

14/06/2024

5

Underperform

$0.90

-28.00%

Of the five concerns raised by the ACCC around the "merger" between Sigma Healthcare and Chemist Warehouse, Macquarie believes the structural change (raising barriers to entry) will be the most challenging to address.

The broker suggests the current risk/reward ratio of a positive outcome is too positively skewed, given increasing prospects of an altered deal.

The Underperform rating and 90c target are unchanged.

The ACCC expects to provide a decision on the proposed transaction on September 5.

FORECAST
Macquarie forecasts a full year FY25 dividend of 1.80 cents and EPS of 3.50 cents.
Macquarie forecasts a full year FY26 dividend of 2.40 cents and EPS of 4.70 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

SIG STOCK CHART

FNArena News on SIG

1
Weekly Ratings, Targets, Forecast Changes – 22-03-24

Mar 25 2024 - Weekly Reports
2
FNArena Corporate Results Monitor – 22-03-2024

Mar 22 2024 - Australia
3
Rudi’s View: Healthcare Under The Scanner

Mar 13 2024 - Rudi's View
4
Weekly Ratings, Targets, Forecast Changes – 12-01-24

Jan 15 2024 - Weekly Reports
5
Weekly Ratings, Targets, Forecast Changes – 15-12-23

Dec 18 2023 - Weekly Reports

Latest Health & Nutrition News

1
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
2
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
3
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
4
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
5
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
6
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
7
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
8
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
9
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
10
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia